ARC-IM (Adaptive Remote Controller - Implantable Module) is an innovative closed-loop deep brain stimulation (DBS) system developed through a collaboration between the École Polytechnique Fédérale de Lausanne (EPFL) and Neuroloop GmbH. This clinical trial represents a significant advancement in neurostimulation therapy for Parkinson's disease by implementing adaptive, biomarker-driven stimulation that adjusts in real-time to patient symptoms.
Traditional DBS systems deliver constant high-frequency stimulation regardless of the patient's current state, which can lead to side effects and inefficient battery use. The ARC-IM system addresses these limitations by continuously monitoring neural signals and adjusting stimulation parameters automatically, providing a more personalized and effective treatment approach.
| Attribute |
Value |
| Trial ID |
NCT06295614 |
| Sponsor |
EPFL / Neuroloop Collaboration |
| Phase |
Phase 1/2 |
| Status |
RECRUITING |
| Condition |
Parkinson's Disease |
| Intervention |
Adaptive Deep Brain Stimulation |
| Target Brain Region |
Subthalamic nucleus or Globus pallidus internus |
| Estimated Enrollment |
20-30 patients |
Traditional deep brain stimulation for Parkinson's disease has been transformative, but has inherent limitations:
- Fixed Stimulation: Delivers constant high-frequency stimulation (130-180 Hz) regardless of patient activity state
- Side Effects: Can cause speech difficulties, gait disturbances, and cognitive issues
- No Adaptation: Cannot respond to diurnal fluctuations in symptoms
- Postural Effects: Stimulation may worsen dyskinesias or postural instability
- Battery Drain: Continuous high-power stimulation shortens device lifespan
Adaptive (closed-loop) DBS represents the next evolution in neurostimulation:
- Biomarker-Driven: Uses neural signals to detect symptom states
- Real-Time Adjustment: Modulates stimulation based on current needs
- Reduced Side Effects: Lower average stimulation intensity
- Improved Efficacy: Better symptom control throughout the day
- Personalized Therapy: Adapts to individual patient patterns
The ARC-IM system consists of several integrated components:
-
Implantable Pulse Generator (IPG)
- Miniaturized neurostimulator
- Rechargeable battery
- Wireless communication
-
Sensing Electrodes
- Dedicated contacts for local field potential (LFP) recording
- Positioned to detect pathological oscillations
- Continuous neural monitoring capability
-
Processing Algorithm
- Real-time signal analysis
- Beta oscillation detection
- Movement-related desynchronization identification
- Artifact rejection
-
Adaptive Controller
- Decision algorithm for stimulation adjustment
- Smooth parameter transitions
- Patient-specific tuning
The ARC-IM system monitors several neural signatures:
- Elevated in the motor cortex and basal ganglia of PD patients
- Correlate with rigidity and bradykinesia
- Suppressed by effective dopaminergic therapy
- Primary trigger for increasing stimulation
- Mu rhythm suppression during movement
- Indicates successful motor execution
- Used to reduce stimulation during voluntary movement
- Tremor-related oscillations
- Gait-related patterns
- Sleep state indicators
- Assess safety and tolerability of adaptive DBS
- Determine optimal biomarker thresholds
- Validate real-time signal processing accuracy
- Compare adaptive vs. conventional DBS efficacy
- Evaluate quality of life improvements
- Assess battery longevity
- Machine learning optimization
- Long-term biomarker stability
- Adaptive protocols for non-motor symptoms
- Age 40-75 years
- Diagnosis of idiopathic Parkinson's disease
- Disease duration >5 years
- Motor complications inadequately controlled by medication
- Eligible for DBS surgery (no contraindications)
- Stable dopaminergic medication for 4+ weeks
- Significant cognitive impairment
- Psychiatric comorbidities
- Previous brain surgery
- Active implants (pacemakers, etc.)
- Unable to comply with study procedures
The ARC-IM trial aims to demonstrate:
- Superior Symptom Control: Better Unified Parkinson's Disease Rating Scale (UPDRS) scores compared to conventional DBS
- Reduced Side Effects: Lower incidence of speech, gait, and cognitive adverse events
- Improved Quality of Life: Better scores on PDQ-39 and other quality of life measures
- Extended Battery Life: Longer time between replacements due to reduced average stimulation
The ARC-IM adaptive DBS system represents several important advances:
- Personalized Medicine: Algorithm adapts to individual neural patterns
- Closed-Loop Technology: First fully implantable adaptive DBS system
- Biomarker Validation: Further validates beta oscillations as therapeutic targets
- Technology Platform: Adaptable to other neurological disorders
- Integration with sensing-enabled pacemakers
- Sleep-wake cycle adaptation
- Multi-center deployment
- FDA and CE marking approvals